The only current drug treatment available for brain cancer is a small molecule therapy called temozolomide, which is typically given after radiation therapy but which is largely ineffective as it cannot cross the blood-brain barrier.
The average life expectancy for someone diagnosed with glioblastoma is 15 months on average - fair to say it's not really cutting it but it's the best we have - FOR THE MOMENT
Temozolomide is sold under the product name TEMODAR and is owned by Merck, definitely one of the biggest pharma companies globally - MC is app. $USD 200B
I'm sure that they are keeping a very close eye on proceedings
Ann: Full size deoxymab PAT-DX3 crosses the blood brain barrier, page-37
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $17.51K | 5.837M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 29968527 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 27089307 | 15 |
View Market Depth
| Last trade - 13.32pm 07/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |